0.76
-0.019(-2.44%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.78 |
| Day High | 0.78 |
| Day Low | 0.75 |
| 52-Week High | 1.65 |
| 52-Week Low | 0.7 |
| Volume | 152,422 |
| Average Volume | 176,715 |
| Market Cap | 59.14M |
| PE | -1.86 |
| EPS | -0.41 |
| Moving Average 50 Days | 0.87 |
| Moving Average 200 Days | 1 |
| Change | -0.02 |
If you invested $1000 in Clearside Biomedical, Inc. (CLSD) since IPO date, it would be worth $104.97 as of June 01, 2025 at a share price of $0.761. Whereas If you bought $1000 worth of Clearside Biomedical, Inc. (CLSD) shares 5 years ago, it would be worth $411.35 as of June 01, 2025 at a share price of $0.761.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
GlobeNewswire Inc.
May 21, 2025 11:05 AM GMT
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
May 14, 2025 8:05 PM GMT
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achie
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
GlobeNewswire Inc.
May 09, 2025 11:05 AM GMT
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular DiseasesALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clear